Arthrex: A Royalty Refused Until the Surgeon Threatened to Leave

In the Arthrex royalty kickback settlement, the orthopedic device maker agreed to pay $16 million to resolve allegations that royalty payments induced a surgeon to use and recommend its products, causing false Medicare claims. The royalties carried the names of SutureBridge and SpeedBridge, its joint-repair kits. The government alleged that a threat to take the surgeon’s business to a competitor helped turn a rejected royalty request into a richer deal covering past and future sales.

The whistleblower’s complaint reported $12,921,953 in royalties to that one surgeon from the second half of 2013 through 2018.

The Department of Justice announced the civil settlement on November 8, 2021. Arthrex is based in Naples, Florida. The whistleblower who brought the False Claims Act case said in his complaint that he had represented Arthrex products in New England and later helped the Colorado orthopedic surgeon negotiate the royalty arrangement.

A Royalty Agreement Negotiated Around the Threat to Leave

The government alleged that Arthrex agreed to the royalties to influence purchasing, ordering and recommendations. The settlement agreement says the company had refused the surgeon’s request in 2006. When he threatened to shift his loyalty to a competitor in 2010, the government said, Arthrex agreed to pay royalties on past and future sales at a rate above its ordinary practice.

SutureBridge and SpeedBridge are packaged sets of anchors and sutures used to complete a surgical procedure. The whistleblower’s complaint described the surgeon’s claimed contribution as a rotator-cuff repair technique. It disputed his entitlement to royalties and alleged that none of the relevant product patents listed him as an inventor. The complaint also named ALM Research LLC, a company the surgeon owned and controlled, and described royalty money received through that company.

The whistleblower alleged that he approached competing device companies to create opportunities for the surgeon, then used those opportunities to press Arthrex for a larger agreement. He alleged that he told Arthrex’s sales leadership the surgeon had other options and continued advising the surgeon during the negotiations.

According to the complaint, the resulting August 2010 deal paid 4% of product revenue from the beginning of that year, with retroactive royalties at 2% on earlier sales. The whistleblower described the lower rate as Arthrex’s customary royalty arrangement. A threat to leave allegedly changed both the rate and the treatment of sales already made.

The payments carried the label of product-development compensation. The government’s allegation was that Arthrex was paying to keep the surgeon buying, ordering and recommending its devices.

How Does Reimbursement Work for Medical Devices?

For the inpatient surgeries described in the complaint, the hospital buys the device and Medicare includes its cost in the payment for the hospital stay. The surgeon separately bills for professional services.

The complaint describes implantable devices as physician-preference items: surgeons select the devices for their operations, while hospitals generally buy them from the manufacturer. That split explains why a manufacturer seeking hospital sales would direct a payment toward a surgeon. The surgeon’s choice can determine which company’s product the hospital purchases.

On the hospital side, the complaint describes a diagnosis-related group payment covering the inpatient surgery’s costs, including the device. On the professional side, the surgeon submits a separate claim to Medicare Part B identifying the procedure performed. The government’s case against Arthrex followed the alleged influence on device choice into those downstream claims.

The government’s stated theory was that Arthrex’s payments induced device purchases and recommendations, causing third parties to submit false Medicare claims. The alleged financial incentive reached medical decision-making before the hospital sent its bill.

The Surgeon Could Influence More Than His Own Operations

The complaint alleged that the surgeon’s value to Arthrex included the choices other surgeons would make after training with him. He trained seven to eight orthopedic fellows a year, according to the whistleblower, and those fellows typically went into practice using products they had learned to use during fellowship.

The complaint describes the broader loyalty expected from surgeons with large royalty agreements:

The alleged bargain reached public speaking and training as well as purchases for the recipient’s own patients. A sales representative or clinical educator may recognize that distinction immediately: the relationship described in the complaint could influence which products another surgeon learned to use, then continued using in practice. The royalty negotiation concerned access to that wider influence.

Open Payments Shows the Money, the Negotiations Explain Its Purpose

The complaint used CMS Open Payments data to identify 50 royalty payments to the surgeon. The public table showed the money, but the complaint’s account of the negotiations explained the alleged bargain behind it.

The table also showed how the descriptions changed. Earlier entries used broad product categories, including shoulder and elbow arthroscopy. Later entries named combinations of products, including SpeedBridge anchors and SutureBridge. The complaint said Arthrex changed its reporting format in 2016, listing products in different orders or under slightly different descriptions, making the precise bases of the payments difficult to discern.

For an insider, that is where the contract and the business records matter. The public entry describes a payment and the products reported with it. The negotiation describes what the parties wanted from the arrangement. Royalty calculations, product-development records and sales communications can connect the two. In this complaint, the whistleblower supplied an account of the pressure to retain the surgeon alongside the reported payments.

The Corporate Settlement and Compliance Agreement

Arthrex’s settlement covered alleged conduct from August 2010 through March 5, 2021. The company also entered a five-year corporate integrity agreement with the Department of Health and Human Services Office of Inspector General. The settlement refers to annual reviews by an independent review organization and reports to OIG.

What Evidence Is Needed to Prove Fraud?

In a medical device royalty case, the evidence needs to connect why the company paid a surgeon with device choices, purchases and government claims. The Arthrex complaint brought those parts together through the negotiation history, the claimed product contribution, payment records and the surgeon’s ability to influence use. We work with insiders to establish those connections from what they know about the business.

The product-development side matters as much as the sales side. The complaint cited AdvaMed’s industry guidance calling for a documented business need, a novel or significant contribution, and compensation based on the contribution’s value. It also described guidance intended to preserve independent medical decisions. The question underneath the paperwork is what contribution the company was paying to obtain.

For someone in product development, the relevant knowledge may concern the work behind the agreement and the products that used it. For someone in sales, it may concern the decision to raise compensation when a surgeon considered a competing product. A payment calculation can show which sales generated royalties. Purchasing and billing records can connect the selected device with the care the government paid for. Each view bears on a different part of the same alleged exchange.

Life Spine admitted in its civil settlement that its management reports tracked surgeon payments alongside those surgeons’ use of its products.

A 2020 paper on healthcare fraud in the Journal of Forensic and Investigative Accounting identifies two strengths of whistleblower cases: access to inside information and knowledgeable whistleblowers supplementing the government’s stretched enforcement resources.

In Arthrex’s case, the whistleblower described conversations and negotiations he had participated in. His account shows why someone who knows how an arrangement was sold, negotiated or measured can explain more than the payment description alone.

How Much Is a Whistleblower Claim Worth?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In Arthrex’s case, the settlement agreement allocated $2.5 million to the whistleblower, paid from the company’s settlement amount.

Our whistleblower experts help turn knowledge of the deal behind a royalty payment into a medical device fraud case.

You Know Why the Royalty Was Offered

If you saw a royalty negotiated around a surgeon’s business, speak to one of our whistleblower experts about the agreement and the sales behind it. We build your case with you and bring in medical device whistleblower lawyers who understand royalty arrangements, physician influence and Medicare claims. We stay beside you as your knowledge of the deal becomes the foundation for pursuing a recovery.